Drugs
May 1, 2025
Sharmin Ghaznavi, Sarah G Richter
6 citations
There has been a recent resurgence in research on psychedelics as therapeutic agents for psychiatric conditions. This leading article outlines the studies to date of classic psychedelic treatments for treatment-resistant depression and major depression, including psilocybin, ayahuasca, dimethyltryptamine (DMT), and O-methyl-bufotenine (5-Me-O DMT). We discuss the potential of expanding...
Nature
April 23, 2025
Elizabeth N. Chung, Jinsu Lee, C. Polonio et al.
Neuroimmune interactions—signals transmitted between immune and brain cells—regulate many aspects of tissue physiology1, including responses to psychological stress2, 3, 4–5, which can predispose individuals to develop neuropsychiatric diseases6, 7, 8–9. Still, the interactions between haematopoietic and brain-resident cells that influence complex behaviours are poorly understood. Here, we use...
The American journal of psychiatry
2025
Sharmin Ghaznavi, Jeremy N Ruskin, Stephen J Haggerty et al.
The last few years have seen exponential growth in interest, investment, advocacy, and research into psychedelics as therapeutics. This reflects an optimism about the potential promise of psychedelics as therapeutics. As with all therapeutic interventions, research is needed not only into their benefits but also potential risks. Indeed, when substances with therapeutic potential are scrutinized...
The Primary Care Companion For CNS Disorders
May 28, 2024
Sharmin Ghaznavi, Lourdes M Bernardez, Theodore A Stern
2 citations
The Psychiatric Consultation Service at Massachusetts General Hospital sees medical and surgical inpatients with comorbid psychiatric symptoms and conditions. During their twice-weekly rounds, Dr Stern and other members of the Consultation Service discuss diagnosis and management of hospitalized patients with complex medical or surgical problems who also demonstrate psychiatric symptoms or...